Metastatic Breast Cancer

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses the learning curve of taking an oral medication, tucatinib, in combination with chemotherapy, and Sara A. Hurvitz, M.D., reviews methods for medication adherence.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses how her quality of life has been since she began taking tucatinib with chemotherapy.

Sara A. Hurvitz, M.D., reviews the advances in HER2+ metastatic breast cancer that have been made over the past decade.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her goals of treatment after progression of disease.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.

A woman who is living with metastatic breast cancer pens a tribute to a late friend and fellow patient, Penny, who continues to send her signs that help her keep going.

A patient with metastatic cancer writes what it has been like to face the dilemma of receiving an effective cancer therapy that may put her heart at risk.

An expert discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates. Each therapy type has an FDA-approved option to potentially provide patients with better outcomes and quality of life.

Sara A. Hurvitz, M.D., reviews the history of HER2+ breast cancer and the progressive research that has been done in this disease.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, describes her experience learning about the surplus of treatment options and how she overcame her initial apprehension.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her initial impression of when she was diagnosed.

Sara A. Hurvitz, M.D., describes the subtypes, staging and grading of breast cancer.

The FDA announced that a special committee will review the indications of several cancer drugs that were granted accelerated approval as confirmatory trials showed they failed to demonstrate efficacy.

As her seven-year cancerversary approaches, one patient with metastatic breast cancer shares why she is grateful to be a 'mutant'.

Vaccine eligibility forces this metastatic breast cancer patient to confront the value society places on her life.

Overdue reminders are often reminders of where we are on the cancer journey.

Skating has been an invaluable part of my life, and one that taught me a crucial lesson for handling life with cancer.

With a terminal illness of metastatic breast cancer, I qualify for Social Security Disability as the COVID-19 pandemic has retired me, but that isn't stopping me from achieving my life goals.

The Breast Cancer Recurrence Project aims to revolutionize and bring accuracy to what we know about who’s living with metastatic breast cancer.

Living beyond the statistics and finding a way to celebrate a “cancerversary” with metastatic breast cancer.

A song can be the gateway to memories on the cancer journey.

Looking back at my journey with wigs, or "the girls", during my early treatment for cancer.

Becoming a dog owner, and the designated dog walker, while my dog and I both moved through cancer treatment is an experience that has shaped my motivation on the cancer journey.

Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.

Data from the trial that led to the Food and Drug Administration approval demonstrated that Margenza plus chemotherapy reduced the risk of disease progression or death in patients with metastatic HER2-positive breast cancer by 24%, compared with Herceptin plus chemotherapy.

Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.

In addition to having greater efficacy, the combination of oral paclitaxel and encequidar demonstrated lower rates of chemotherapy-induced peripheral neuropathy in patients with metastatic breast cancer compared to intravenous paclitaxel.

My grandpa always lived life to the fullest, until the day he couldn't. And while he did, he didn't have to know about my cancer diagnosis.